December 21, 2022 (Richmond, California) AIM at Melanoma is proud to announce that its strong financial health and ongoing accountability and transparency has earned a Four-Star Rating from Charity Navigator. This rating designates AIM at Melanoma as an official “Give with Confidence” charity, indicating that our organization is using its donations effectively based on Charity Navigator’s criteria. Charity Navigator is America’s largest and most-utilized independent charity evaluator. Since 2001, the organization has been an unbiased and trusted source of information for more than 11 million donors annually.
Charity Navigator analyzes nonprofit performance based on four key indicators, referred to as beacons. Currently, nonprofits can earn scores for the Impact & Results, Accountability & Finance, Culture & Community, and Leadership & Adaptability beacons.
“We are delighted to provide AIM at Melanoma with third-party accreditation that validates their operational excellence,” said Michael Thatcher, President and CEO of Charity Navigator. “The Four-Star Rating is the highest possible rating an organization can achieve. We are eager to see the good work that AIM at Melanoma is able to accomplish in the years ahead.”
“Our Four-Star Charity Navigator rating is further validation that our supporters can trust our commitment to good governance and financial health,” said Samantha Guild, AIM at Melanoma’s President. “We hope that it will introduce our work to new supporters who can help us advance our mission to end this disease in our lifetime and improve the lives of those it affects.”
AIM at Melanoma’s rating and other information about charitable giving are available free of charge on charitynavigator.org.
AIM at Melanoma is proud of its impact over the last 15+ years. From its modest roots operating out of the living room of its founder, Valerie Guild, after she lost her 26-year-old daughter to melanoma, AIM has grown to be a global foundation whose work focuses on three critical areas: innovative and collaborative research; legislation, policy, and advocacy; and education. AIM at Melanoma’s foundation principles include the understanding that melanoma is a global disease, and to both prevent the disease and identify successful therapies, we must work globally and collaboratively. AIM is based in the United States, but we work with researchers, advocates, policymakers, and patients around the world.
AIM’s global research initiatives include The International Melanoma Tissue Bank Consortium, The Melanoma International Collaboration for Adaptive Trials, and The International Melanoma Working Group. AIM at Melanoma provides education, connection to resources and opportunities for meaningful engagement to help patients and caregivers/families better face the challenges of melanoma. Founded in 2004, AIM at Melanoma is dedicated to finding more effective treatments and, ultimately, the cure for melanoma while improving the lives of those it affects.
Melanoma is one of the fastest-growing cancers in the United States and worldwide. It’s one of the most complex forms of cancer and has the most mutations of all solid cancers. In the U.S., melanoma is the third most common cancer among men and women ages 20-39. Incidence rates are higher in women than in men before the age of 50, but by age 65, rates in men double those in women, and by age 80, they are triple.